Biologic aspects of ADHD and conduct disorders in childhood and adolescence, selected preventive aspects

1. Polanczyk G, Jansen P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin N Am 2008; 17: 245–260.

2. Greenhill LL, Kollins S, Abikoff H et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45: 1284–1293.

3. Hunt RD, Lau S, Ryu J. Alternative therapies for ADHD. In: Greenhill LL, Osamn BB (eds.). Ritalin: Theory and patient management. Mary Ann Liebert, New York, 1991: 75–95.

4. Hunt RD. Treatment effects of oral and transdermal clonidine in relation to methylphenidate. An open pilot study in ADD-H. Psychopharmacol Bull 1987; 23: 111–114.

5. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994; 33: 424–426.

6. Biedermann J, Munir K, Knee D et al. A family study of patients with attention deficit disorder and normal controls. J Psychiatr Res 1986; 20: 263–284.

7. Safer DJA. Familial factor in minimal brain dysfunction. Behav Genet 1973; 3: 175–186.

8. Stevenson J. Evidence for a genetic etiology in hyperactivity in children. Behav Genet 1992; 22: 337–344.

9. Hechtman L. Genetic and neurobiological aspects of attention deficit hyperactivity disorder: a review. J Psychiatry Neurosci 1994; 19: 193–201.

10. Edelbrock C, Rende R, Plomin R, Thompson LA. A twin study of competence and problem behaviour in childhood and early adolescence. J Child Psychol Psychiatry 1995; 36: 775–785.

11. Spencer T, Biederman J, Wilens T et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–432.

12. Shaywitz BA, Cohen DJ, Bowers MB. CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. J Pediatr 1977; 90: 67–71.

13. Castellanos FX, Giedd JN, Eckburg P et al. Quantitative morphology of the caudate nucleus in Attention Deficit Hyperactivity Disorder. Am J Psychiatry 1994; 151: 1791–1796.

14. Ernst M. Presynaptic dopaminergic activity in adults and children with ADHD by PET and (fluorine-18) fluorodopa. Attention Deficit Hyperactivity Disorder. IBC, Boston, 1997.

15. Maldonado R, Saiard A, Valeverde O et al. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997; 388: 586–589.

16. Volkow ND, Ding U, Fowler JS et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 1995; 52: 456–463.

17. Comings DE. Genetics of ADHD. IBC’s International Conference on Dopaminergic Disorders Novel Approaches for Drug Discovery and Development, Boston, 1997.

18. Šerý O, Theiner P, Hladilová R et al. Geny pro Il-6 a DRD2 souvisejí s hyperkinetickou poruchou. Česká a slovenská psychiatrie 2003; 99: 404–409.

19. Šerý O, Drtílková I, Theiner P et al. Polymorphism of DRD2 gene and ADHD. Neuro Endocrinol Lett 2006; 27: 236–240.

20. Kopečková M, Paclt I, Petrásek J et al. Some ADHD polymorphisms (in genes DAT1, DRD2, DRD3, DBH, 5-HTT) in case-control study of 100 subjects 6–10 age. Neuro Endocrinol Lett 2008; 29: 246–251.

21. Paclt I, Drtílková I, Kopečková M et al. The association between TaqI A polymorphism of ANKK1 (DRD2) gene and ADHD in the Czech boys aged between 6 and 13 years. Neuro Endocrinol Lett 2010; 31: 131–136.

22. Rowe DC, Van den Oord EJ, Stever C et al. The DRD2 TaqI polymorphism and symptoms of attention deficit hyperactivity disorder. Mol Psychiatry 1999; 4: 580–586.

23. Todd RD, Lobos EA. Mutation screening of the dopamine D2 receptor gene in attention-deficit hyperactivity disorder subtypes: preliminary report of a research strategy. Am J Med Genet 2002; 114: 34–41.

24. Lasky-Su J, Neale BM, Franke B et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1345–1354.

25. Lasky-Su J, Anney RJL, Neale BM et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1355–1358.

26. Brookes K, Xu X, Chen W et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 2006; 11: 934–953.

27. Civelli O, Bunzow JR, Grandy DK et al. Molecular biology of the dopamine receptors. Eur J Pharmacol 1991; 207: 277–286.

28. Lichter JB, Barr CL, Kennedy JL et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767–773.

29. Asghari V, Sanyal S, Buchwaldt S et al. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157–1165.

30. Durston S. Imaging genetics in ADHD. Neuroimage 2010; 53: 832–838.

31. LaHoste GJ, Swanson JM, Wigal SB et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121–124.

32. Smalley LS. Genetic influences in childhood-onset psychiatric disorders autism and attention-deficit/hyperactivity disorder. Am J Hum Genet 1997; 60: 1276–1282.

33. DiMaio S, Grizenko N, Joober R. Dopamine genes and attention-deficit hyperactivity disorder: a review. J Psychiatry Neurosci 2003; 28: 27–38.

34. Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006; 15: 2276–2284.

35. El-Faddagh M, Laucht M, Maras A et al. Association of dopamine D4 receptor (DRD4) gene with attention-deficit/hyperactivity disorder (ADHD) in a high-risk community sample: a longitudinal study from birth to 11 years of age. J Neural Transm (Vienna) 2004; 111: 883–889.

36. Giros B, Jaber M, Jones SR et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606–612.

37. Kemper CM, O’Connor DT, Westlund KN. Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neuroscience 1987; 23: 981–989.

38. Viveros H, Somjen GG. Magnesium-calcium antagonism in the contraction of arterioles. Experientia 1968; 24: 457–459.

39. Brown GL, Ebert MH, Hunt RD, Rapoport JL. Urinary 3-methoxy-4-hydroxyphenylglycol and homovanillic acid response to d-amphetamine in hyperactive children. Biol Psychiatry 1981; 16: 779–787.

40. Yasong D, Linyan S, Xuerong L. Measurement of serum catecholamines in boys with attention deficit hyperactivity disorder. Chin J Psychiatry 1998; 31: 30–33.

41. Wigg K, Zai G, Schachar R et al. Attention deficit hyperactivity disorder and the gene for dopamine beta-hydroxylase. Am J Psychiatry 2002; 159: 1046–1048.

42. Hawi Z, Lowe N, Kirley A et al. Linkage disequilibrium mapping at DAT 1, DRD 5 and DBH narrows the search for ADHD susceptibility alleles at these loci. Mol Psychiatry 2003; 8: 299–308.

43. Pastura G, Mattos P, Gasparetto EL, Araújo AP. Advanced techniques in magnetic resonance imaging of the brain in children with ADHD. Arq Neuropsiquiatr 2011; 69: 242–252.

44. Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61: 1361–1369.

45. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: The search for endophenotypes. Nat Rev Neurosci 2002; 3: 617–628.

46. Frodl T, Skokauskas N. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr Scand 2012; 125: 114–126.

47. Czerniak SM, Sikoglu EM, King JA et al. Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review. Harv Rev Psychiatry 2013; 21: 151–162.

48. Giedd JN, Snell JW, Lange N et al. Quantitative magnetic resonance imaging of human brain development: ages 4–18. Cereb Cortex 1996; 6: 551–560.

49. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011; 168: 1154–1163.

50. Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1285–1292.

51. Bielsa A. Conduct disorder: Treatment. Abstracts book. 16th World Congress of the IACAPAP, Berlin, 2004: 40–41.

52. Mohler B. The place of the psychotropic drugs with violent adolescents. Abstracts book. 16th World Congress of the IACAPAP, Berlin, 2004: 147–148.

53. Reyes M, Buitelaar J, Augustyns I, Eerdekens M. Risperidone prevents relapse of disruptive behavioral disorders in children and adolescents of average intelligence: a 6-month trial of risperidone versus placebo. Programme and abstracts book. Pediatric CNS Educational Symposium, Vídeň, 2005: 26.

54. Reyes-Harde M, Croonenberhs J, Augustyns I, Eerdekens M. Risperidone in children with disruptive behavior disorders: 2 years of data. Programme and abstracts book. Pediatric CNS Educational Symposium, Vídeň, 2005: 24.

55. Turgay A. Treatment of disruptive behaviour disorders. Programme and abstracts book. Pediatric CNS Educational Symposium, Vídeň, 2005: 24.

56. Findling RL. The acute effectiveness and pharmacokinetics of quetiapine in conduct disorder. AACAP/CACAP, Scientific Proceedings, Toronto, 2005: 176.

57. Correll Ch. Changes in body composition and serum lipids in children and adolescents treated with second generation antipsychotics. 16th World Congress of the IACAPAP, Berlin, 2004.

58. Gabel S, Stadler J, Bjorn J et al. Biodevelopmental aspects of conduct disorder in boys. J Child Psychol Hum Dev 1993; 24: 125–141.

59. Rappaport J, Quinn P, Lambrecht F. Minor physical anomalies and plasma dopamine-beta-hydroxylase activity in hyperactive boys. Am J Psychiatry 1974, 131: 386–390.

60. Koudelová J, Paclt I, Mourek J, Trojan S. Variability in dopamin-beta-hydroxylase activity in plasma of rats (the effect of age and of hypoxia in plasma of children with mental disorders). In: Van Loun CR, Kvetňanský K, McCarthy R, Axelrod J (eds.). Stress: Neurochemical and Humoral Mechanisms. Gordon and Break Science Publishers S. A., New York, 1989: 967–974.

61. Rogeness GA, Crawford L, McNamara A. Plasma dopamine-beta-hydroxylase and preschool behaviour in children with conduct disorder. Child Psychiatry Hum Dev 1989; 20: 149–156.

62. Rogeness GA, Maas JW, Javors MA et al. Attention deficit disorder symptoms and urine catecholamines. Psychiatry Res 1989; 27: 241–251.

63. Galvin M, Ten Eyck R, Shekhar A et al. Serum dopamine-beta-hydroxylase and maltreatment in psychiatrically hospitalized boys. Child Abuse Negl 1995; 19: 821–832.

64. Galvin M, Stilwell BM, Shekhar A et al. Maltreatment, conscience functioning and dopamine-beta-hydroxylase in emotionally disturbed boys. Child Abuse Negl 1997; 21: 83–92.

65. Paclt I, Koudelová J. Activity of the dopamine-beta-hydroxylase (DBH) in experiments in animals, in norms and in humans suffering with special developmental dopaminergic disorders. IBC ADHD conference, Boston, 1997.

66. Comings DE, Gade Andavolu R, Gonzales N et al. Additive effect of three noradrenergic genes (ADRA2A, ADRA2C, DBH) on attention deficit hyperactivity disorder and learning disabilities in Tourette’s syndrome subjects. Clin Genet 1999; 55: 160–172.

67. Bowden CL, Deutsch CK, Swanson JM. Plasma dopamine-beta-hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct disorder. J Am Acad Child Adolesc Psychiatry 1988; 27: 171–174.

68. Waldman ID, Rowe DC, Abramowitz A et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998; 63: 1767–1776.